Decibel Therapeutics Announces Extension of Research Term with Regeneron for Development of Gene Therapy Hearing Loss Treatments
BOSTON, MASSACHUSSETTS –– Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss. The research term will be extended…
Read More
Decibel Therapeutics Reports Q3 2021 Financial Results and Corporate Update
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Decibel continues to work towards bringing transformative treatments to patients with hearing and balance…
Read MoreDecibel Therapeutics Announces Publication of Foundational Study of Noise-Induced Inner Ear Damage
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have…
Read More
Decibel Therapeutics Gene Therapy Hearing Loss Treatment, DB-OTO, Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the…
Read More
Decibel Therapeutics Announces Pricing of Initial Public Offering; Raises $127M
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the pricing of its initial public offering (IPO) of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares…
Read More
Decibel Therapeutics and Catalent Partner to Develop Gene Therapy for Treatment of Congenital Hearing Loss
SOMERSET, NEW JERSEY & BOSTON, MASSACHUSSETTS — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, today announced they have signed…
Read More
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing treatments to restore and improve hearing and balance, has announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy.…
Read MoreDecibel Therapeutics Files for $75 Million IPO
BOSTON, MASSACHUSSETS — Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering (IPO). The news was first reported by IPO investment manager Renaissance Capital. The company is the latest…
Read More
Decibel Therapeutics Announces DB-020 Granted Fast Track Designation by the FDA
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss,…
Read MoreDecibel Therapeutics Raises $82M to Advance Gene Therapies to Restore Hearing and Balance
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2M. The financing was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor…
Read More